Evidence map›Paper›PMID 42569222›Full record

ArticleMaterials today. Bio2026

Macrophage-reprogramming calcium alginate microspheres enhance exosome-mediated antigen cross-presentation to boost embolization-immunotherapy in hepatocellular carcinoma.

Xiaoju Guo, Shiji Fang, Liyun Zheng, Mengzhu Han, Yiming Ding, Jiale Chen, Pan Qin, Yeyu Zhang, Gaofeng Shu, Zhongwei Zhao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xiaoju GuoZhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Shiji FangZhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Liyun ZhengZhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Mengzhu HanZhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Yiming DingZhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Jiale ChenZhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Pan QinZhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Yeyu ZhangZhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Gaofeng ShuZhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Zhongwei ZhaoZhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Xiaoqiang LiSuzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, 215163, China.
Chenying LuZhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Minjiang ChenZhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Jiansong JiZhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transarterial chemoembolization (TACE) is a first-line therapeutic modality for hepatocellular carcinoma (HCC). Nevertheless, its therapeutic efficacy remains constrained by the hostile tumor microenvironment (TME), typified by acidity and an immunosuppressive milieu. Here, multifunctional microspheres (RC6CaAlgMS) were developed to neutralize the acidic TME and relieve immunosuppression. The uniform-sized calcium alginate microspheres were fabricated using microfluidic technology, incorporating pH-responsive CaCO

Indexed as

Exosome-mediated antigen cross-presentationHepatocellular carcinomaImmunotherapyMicrospheresTACETumor-associated macrophages

Identifiers

PMID42569222
PMCPMC13449422

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.